polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
SUFLAVE is an oral bowel preparation solution containing polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride. It is used for cleansing the colon prior to colonoscopy, barium enema, or other colorectal procedures. The formulation works as an osmotic laxative, drawing fluid into the bowel to produce evacuation.
Early-stage post-launch product in growth phase with modest Medicare claims volume, indicating emerging market penetration and potential for commercial team expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
SUFLAVE currently shows minimal linked job openings, reflecting its recent approval and early commercialization stage. Career opportunities will likely expand as the brand scales market penetration and builds out commercial infrastructure.
Worked on SUFLAVE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo